SCIOS, Inc. A biopharmaceutical

[101Dahlias]

Press Release
http://biz.yahoo.com/prnews/000829/ca_scios_m.html

Tuesday August 29, 2:01 pm Eastern Time

SOURCE: Scios Inc.

Scios Announces Medical Affairs Vice President

SUNNYVALE, Calif., Aug. 29 /PRNewswire/ -- Scios Inc. (Nasdaq: SCIO - news) today announced the promotion of Darlene Horton, M.D. to the position of Vice President, Medical Affairs. Dr. Horton will also become a member of the Corporate Management Committee. Dr. Horton has been with Scios since 1996, most recently as Senior Director, Clinical Research and Clinical Information Systems.

Responsibilities of Dr. Horton's new position include overseeing the clinical research and clinical information systems groups at Scios. Richard B. Brewer, President and Chief Executive Officer of Scios, noted that, ``Dr. Horton's leadership of the Natrecor development program is evident by the on-schedule completion of the VMAC trial last month. She was instrumental in the design of the trial, strategically directing the complex protocol based on FDA and outside expert input. Dr. Horton's experience as a practicing cardiologist will be extremely useful in the development of additional clinical programs for Natrecor as we near approval.''

Dr. Horton received her medical degree from the University of Florida, Gainesville in 1988. Dr. Horton completed her residency in the Department of Pediatrics at the University of California, San Francisco. Prior to joining Scios, Dr. Horton completed her fellowship in pediatric cardiology at UCSF's Cardiovascular Research Institute, during which time her clinical and research focus was adult electrophysiology.

Scios Inc.

Scios is a biopharmaceutical company engaged in the discovery, development, and commercialization of novel human therapeutics. Scios has commercial or research and development relationships with Chiron Corporation, DuPont Pharmaceuticals Company; Eli Lilly and Company; GenVec, Inc.; Kaken Pharmaceutical Co., Ltd.; and Novo Nordisk A/S, of Denmark. Additional information on Scios is available at its web site located at www.sciosinc.com and in the company's various filings with the Securities and Exchange Commission.

The statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties. These include the risks concerning the success of the VMAC trial, regulatory approval of Natrecor as a treatment for acute decompensated CHF, and development of additional clinical uses for Natrecor, as well as other risks detailed from time to time in the reports filed by Scios with the SEC, including the company's annual report on form 10-K for the year ended December 31, 1999 and subsequent reports on form 10-Q.

SOURCE: Scios Inc.